Click for best price
Nonalcoholic Steatohepatitis NASH Market Size, Share 2023
| Market size in 2022 |
US$ 3152.9 million
|
Forecast Market size by 2029 |
US$ 41860 million
|
| Growth Rate |
CAGR of 44.7% |
Number of Pages |
66 Pages |
Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
This report aims to provide a comprehensive presentation of the global market for Nonalcoholic Steatohepatitis (NASH), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nonalcoholic Steatohepatitis (NASH). This report contains market size and forecasts of Nonalcoholic Steatohepatitis (NASH) in global, including the following market information:
Global Nonalcoholic Steatohepatitis (NASH) Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Nonalcoholic Steatohepatitis (NASH) market was valued at US$ 3152.9 million in 2022 and is projected to reach US$ 41860 million by 2029, at a CAGR of 44.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
We surveyed the Nonalcoholic Steatohepatitis (NASH) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Nonalcoholic Steatohepatitis (NASH) Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Nonalcoholic Steatohepatitis (NASH) Market Segment Percentages, by Type, 2022 (%)
Obeticholic acid?OCA?
Selonsertib
Global Nonalcoholic Steatohepatitis (NASH) Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Nonalcoholic Steatohepatitis (NASH) Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Online Provider
Retail Pharmacy
Global Nonalcoholic Steatohepatitis (NASH) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Nonalcoholic Steatohepatitis (NASH) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Nonalcoholic Steatohepatitis (NASH) revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Nonalcoholic Steatohepatitis (NASH) revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Outline of Major Chapters:
Chapter 1: Introduces the definition of Nonalcoholic Steatohepatitis (NASH), market overview.
Chapter 2: Global Nonalcoholic Steatohepatitis (NASH) market size in revenue.
Chapter 3: Detailed analysis of Nonalcoholic Steatohepatitis (NASH) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nonalcoholic Steatohepatitis (NASH) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Nonalcoholic Steatohepatitis (NASH) Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 3152.9 million
|
| Forecast Market size by 2029 |
US$ 41860 million
|
| Growth Rate |
CAGR of 44.7% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
66 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Nonalcoholic Steatohepatitis (NASH) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Nonalcoholic Steatohepatitis (NASH) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Nonalcoholic Steatohepatitis (NASH) Overall Market Size
2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size: 2022 VS 2029
2.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Nonalcoholic Steatohepatitis (NASH) Players in Global Market
3.2 Top Global Nonalcoholic Steatohepatitis (NASH) Companies Ranked by Revenue
3.3 Global Nonalcoholic Steatohepatitis (NASH) Revenue by Companies
3.4 Top 3 and Top 5 Nonalcoholic Steatohepatitis (NASH) Companies in Global Market, by Revenue in 2022
3.5 Global Companies Nonalcoholic Steatohepatitis (NASH) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Nonalcoholic Steatohepatitis (NASH) Players in Global Market
3.6.1 List of Global Tier 1 Nonalcoholic Steatohepatitis (NASH) Companies
3.6.2 List of Global Tier 2 and Tier 3 Nonalcoholic Steatohepatitis (NASH) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Nonalcoholic Steatohepatitis (NASH) Market Size Markets, 2022 & 2029
4.1.2 Obeticholic acid?OCA?
4.1.3 Selonsertib
4.2 By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue & Forecasts
4.2.1 By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2023
4.2.2 By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2024-2029
4.2.3 By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Nonalcoholic Steatohepatitis (NASH) Market Size, 2022 & 2029
5.1.2 Hospital Pharmacy
5.1.3 Online Provider
5.1.4 Retail Pharmacy
5.2 By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue & Forecasts
5.2.1 By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2023
5.2.2 By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2024-2029
5.2.3 By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Nonalcoholic Steatohepatitis (NASH) Market Size, 2022 & 2029
6.2 By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue & Forecasts
6.2.1 By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2023
6.2.2 By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2024-2029
6.2.3 By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2029
6.3.2 US Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.3.3 Canada Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.3.4 Mexico Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2029
6.4.2 Germany Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.4.3 France Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.4.4 U.K. Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.4.5 Italy Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.4.6 Russia Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.4.7 Nordic Countries Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.4.8 Benelux Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2029
6.5.2 China Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.5.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.5.4 South Korea Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.5.5 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.5.6 India Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2029
6.6.2 Brazil Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.6.3 Argentina Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2029
6.7.2 Turkey Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.7.3 Israel Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.7.4 Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
6.7.5 UAE Nonalcoholic Steatohepatitis (NASH) Market Size, 2018-2029
7 Nonalcoholic Steatohepatitis (NASH) Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.1.4 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Arena Pharmaceuticals
7.2.1 Arena Pharmaceuticals Company Summary
7.2.2 Arena Pharmaceuticals Business Overview
7.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.2.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.2.5 Arena Pharmaceuticals Key News & Latest Developments
7.3 GSK
7.3.1 GSK Company Summary
7.3.2 GSK Business Overview
7.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.3.4 GSK Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.3.5 GSK Key News & Latest Developments
7.4 Novo Nordisk
7.4.1 Novo Nordisk Company Summary
7.4.2 Novo Nordisk Business Overview
7.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.4.4 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.4.5 Novo Nordisk Key News & Latest Developments
7.5 Roche
7.5.1 Roche Company Summary
7.5.2 Roche Business Overview
7.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.5.4 Roche Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.5.5 Roche Key News & Latest Developments
7.6 Vivus
7.6.1 Vivus Company Summary
7.6.2 Vivus Business Overview
7.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.6.4 Vivus Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.6.5 Vivus Key News & Latest Developments
7.7 Arisaph Pharmaceuticals
7.7.1 Arisaph Pharmaceuticals Company Summary
7.7.2 Arisaph Pharmaceuticals Business Overview
7.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.7.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.7.5 Arisaph Pharmaceuticals Key News & Latest Developments
7.8 Cempra Pharmaceuticals
7.8.1 Cempra Pharmaceuticals Company Summary
7.8.2 Cempra Pharmaceuticals Business Overview
7.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.8.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.8.5 Cempra Pharmaceuticals Key News & Latest Developments
7.9 Galectin Therapeutics
7.9.1 Galectin Therapeutics Company Summary
7.9.2 Galectin Therapeutics Business Overview
7.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.9.4 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.9.5 Galectin Therapeutics Key News & Latest Developments
7.10 Galmed Pharmaceuticals
7.10.1 Galmed Pharmaceuticals Company Summary
7.10.2 Galmed Pharmaceuticals Business Overview
7.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.10.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.10.5 Galmed Pharmaceuticals Key News & Latest Developments
7.11 Genfit
7.11.1 Genfit Company Summary
7.11.2 Genfit Business Overview
7.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.11.4 Genfit Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.11.5 Genfit Key News & Latest Developments
7.12 Gilead
7.12.1 Gilead Company Summary
7.12.2 Gilead Business Overview
7.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Major Product Offerings
7.12.4 Gilead Nonalcoholic Steatohepatitis (NASH) Revenue in Global Market (2018-2023)
7.12.5 Gilead Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Nonalcoholic Steatohepatitis (NASH) Market Opportunities & Trends in Global Market
Table 2. Nonalcoholic Steatohepatitis (NASH) Market Drivers in Global Market
Table 3. Nonalcoholic Steatohepatitis (NASH) Market Restraints in Global Market
Table 4. Key Players of Nonalcoholic Steatohepatitis (NASH) in Global Market
Table 5. Top Nonalcoholic Steatohepatitis (NASH) Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Companies, 2018-2023
Table 8. Global Companies Nonalcoholic Steatohepatitis (NASH) Product Type
Table 9. List of Global Tier 1 Nonalcoholic Steatohepatitis (NASH) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Nonalcoholic Steatohepatitis (NASH) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Nonalcoholic Steatohepatitis (NASH) Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Nonalcoholic Steatohepatitis (NASH) Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Nonalcoholic Steatohepatitis (NASH) Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Nonalcoholic Steatohepatitis (NASH) Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2024-2029
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 32. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Arena Pharmaceuticals Company Summary
Table 35. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 36. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 37. Arena Pharmaceuticals Key News & Latest Developments
Table 38. GSK Company Summary
Table 39. GSK Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 40. GSK Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 41. GSK Key News & Latest Developments
Table 42. Novo Nordisk Company Summary
Table 43. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 44. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 45. Novo Nordisk Key News & Latest Developments
Table 46. Roche Company Summary
Table 47. Roche Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 48. Roche Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 49. Roche Key News & Latest Developments
Table 50. Vivus Company Summary
Table 51. Vivus Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 52. Vivus Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 53. Vivus Key News & Latest Developments
Table 54. Arisaph Pharmaceuticals Company Summary
Table 55. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 56. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 57. Arisaph Pharmaceuticals Key News & Latest Developments
Table 58. Cempra Pharmaceuticals Company Summary
Table 59. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 60. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 61. Cempra Pharmaceuticals Key News & Latest Developments
Table 62. Galectin Therapeutics Company Summary
Table 63. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 64. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 65. Galectin Therapeutics Key News & Latest Developments
Table 66. Galmed Pharmaceuticals Company Summary
Table 67. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 68. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 69. Galmed Pharmaceuticals Key News & Latest Developments
Table 70. Genfit Company Summary
Table 71. Genfit Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 72. Genfit Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 73. Genfit Key News & Latest Developments
Table 74. Gilead Company Summary
Table 75. Gilead Nonalcoholic Steatohepatitis (NASH) Product Offerings
Table 76. Gilead Nonalcoholic Steatohepatitis (NASH) Revenue (US$, Mn) & (2018-2023)
Table 77. Gilead Key News & Latest Developments
List of Figures
Figure 1. Nonalcoholic Steatohepatitis (NASH) Segment by Type in 2022
Figure 2. Nonalcoholic Steatohepatitis (NASH) Segment by Application in 2022
Figure 3. Global Nonalcoholic Steatohepatitis (NASH) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Nonalcoholic Steatohepatitis (NASH) Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2022
Figure 8. By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 9. By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 10. By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 12. By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 14. By Region - Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 15. By Country - North America Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 16. US Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 20. Germany Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 21. France Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 28. China Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 32. India Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 34. Brazil Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue Market Share, 2018-2029
Figure 37. Turkey Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Nonalcoholic Steatohepatitis (NASH) Revenue, (US$, Mn), 2018-2029
Figure 41. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. GSK Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Roche Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Vivus Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Genfit Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Gilead Nonalcoholic Steatohepatitis (NASH) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
